AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...

We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...

With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...